Lonza
Lonza is a healthcare manufacturing organization helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. They help their customers to deliver new and innovative medicines that treat a wide range of diseases, allowing their patients to benefit from life-saving and life-enhancing treatments.
Latest Lonza Content
Product
Advertisement
Human Hepatocytes, Cryopreserved, Plateable and Interaction Qualified
Lonza's cryopreserved, plateable human hepatocytes, HUCPI, are characterized for transporter activity, enzyme activity, and enzyme gene induction potential.
Donor-matched NPCs are available. All liver-derived cells have an optimized media system for thawing, plating, and maintenance.
Donor-matched NPCs are available. All liver-derived cells have an optimized media system for thawing, plating, and maintenance.
Product
Advertisement
Human Peripheral Blood Mononuclear Cells (PBMCs)
Peripheral blood mononuclear cells (PBMCs), are increasingly being used in the drug development pipeline for biological therapeutics.
App Note / Case Study
Assessing the Functionality of PBMCs After Cryopreservation
As PBMCs continue to see an increase in use in the testing of new biological therapeutic compounds, ensuring purified cells retain functionality after cryopreservation is critical.
Product News
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Wolfgang Wienand, currently CEO of Swiss CDMO Siegfried Holding AG, will become Chief Executive Officer of Lonza in the summer of 2024. Albert M. Baehny will retire from Lonza following a transition period.
eBook
Drug Discovery: Current Approaches and Future Perspectives
Through a selection of articles, interviews and graphics, this eBook will provide readers with an overview of drug discovery, design and development, highlighting challenges and solutions, successes, various modalities and approaches.
Product News
Lonza and Oxford Nanopore To Collaborate on Novel Test To Accelerate Analysis of mRNA Products
Collaboration aims to commercialize a Current Good Manufacturing Practice (cGMP) validated test to enable advanced and innovative analysis for multiple critical quality attributes of mRNA products.
Product News
Jean-Marc Huët To Succeed Albert M. Baehny as Chairman of Lonza
Longstanding Chairman of Lonza, Albert Baehny will not stand for re-election. Jean-Marc Huët, currently Chairman of Heineken N.V. with strong international leadership track record to be proposed as the new Chairman of Lonza at the 2024 AGM.
Product News
Lonza Delivers Solid 2023 Performance With 10.9% Cer Sales Growth and 29.8% Core EBITDA Margin
Lonza has reported sales of CHF 6.7 billion, sales growth of 7.9% AER2 (10.9%1 CER), and CHF 2 billion CORE EBITDA, resulting in a margin of 29.8%.
Industry Insight
Maximizing Cell Line Productivity and Efficiency
In this interview, Dr. Tabitha Bullock tells us about some of the key considerations in cell line development and how advances in technology are improving the efficiency and productivity of cell lines.
Product News
Lonza’s Rapid PyroCell® Monocyte Activation Test Systems Make Rabbit-Free Pyrogen Testing Faster, Easier, and More Efficient
Lonza launched PyroCell® MAT Rapid System and PyroCell® MAT Human Serum (HS) Rapid System, two sustainable monocyte activation test (MAT) systems containing the new PeliKine Human IL-6 Rapid ELISA Kit.
Advertisement
